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female; 48% control patients. Overall, 15.8% of patients experienced hyperkalemia: 
9.8% had ≥ 1 mild hyperkalemia event and 6.1% had moderate/severe events. 8.5% of 
control patients experienced hyperkalemia events compared with 23.5% of patients 
with HF, 29.5% of patients with CKD stages 3-4, and 47.6% of patients with HF and 
CKD stages 3-4. Hyperkalemia was more prevalent in patients with each measured 
comorbidity compared to control patients, and its severity increased with CKD sever-
ity (all comparisons, P< 0.0001). Moderate/severe hyperkalemia was more prevalent in 
patients with later-stage CKD compared to patients with earlier stage kidney disease. 
Prevalence of hyperkalemia was generally higher in patients aged ≥ 65 years than in 
similarly comorbid patients aged < 65 years. ConClusions: A retrospective analysis 
of electronic medical record data demonstrated that hyperkalemia was more common 
in patients with HF and/or CKD —especially in those with more advanced disease—
than in patients without these comorbidities.
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objeCtives: describe the national prevalence of deep vein thrombosis (DVT) and 
pulmonary embolism (PE), among patients hospitalized in private and public French 
hospitals and to compare it to those described in US Hospitals. Methods: The 
statistics are from the national PMSI MCO databases inspired by the US Medicare 
system. Data are encoded using ICD10. The codes used for VTE are I801 to I809 
for DVT and codes I260, I269 for PE. The analyses identify all VTE, DVT without PE 
(DVT) and PE with or without previous/associated DVT. The study data cover the 
period 2005 to 2011. The French data are compared to those issued in the Morbidity, 
Mortality Weekly Report of the Centre for Disease Control and Prevention. Results: 
Data from the national database reveal that over the period 2005 to 2011 the inci-
dence of hospital stays came to 860 343 (1.09%) for VTE, with 428 261 (0.543%) for 
DVT without PE and 432 082 (0.548%) for PE. The mean number of VTE hospitalized 
per year over the period was 122 906, including 61 180 for DVT and 61 726 for PE. 
Out of the French population > 18y, those 122 906 VTE correspond to an incidence of 
247 hospitalizations for 100 000 vs. 239 in the USA for the VTE, of 124 vs. 118 for the 
DVT without EP and of 123 vs. 121 for the EP which is very similar. These instances 
of VTE occurred in France for 43.4% in men vs. 45.8% in the USA and 56.6% vs. 
54.2% in women. ConClusions: French VTE incidence is high and similar to those 
described in the USA. These results point out an alarming situation that questions 
the quality of prevention and/or its effectiveness. VTE prevention policies must 
be strengthened in hospitals for the sake of patients and healthcare savings alike.
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objeCtives: The differences in prevalence and odds ratios of self-reported hyper-
tension among racial/ethnic groups in the United States have not been fully 
explained. This current study focused on investigating the prevalence and the joint 
effect of multiple risk factors on self-reported hypertension in the United States 
ethnic subgroups. Methods: A cross-sectional study design was used to determine 
the prevalence of self-reported hypertension among non-Hispanic whites, non-
Hispanic blacks, and Hispanics in the National Health Interview Survey (NHIS), 2004 
– 2013. An estimated total of 607 million cases of self-reported hypertension among 
United States adults 18 years or older was identified. Logistic regression models 
were utilized to estimate the odds ratios (OR) and 95% confidence intervals for the 
selected risk factors associated with hypertension. Results: The overall prevalence 
of self-reported hypertension in the non-Hispanic whites, non-Hispanic blacks, and 
Hispanics was 29.4%, 35.4%, and 19.5% respectively. After adjusting for the selected 
risk factors , a subgroup analysis of subjects aged 18-44 years non-Hispanic black 
males and females were found to have statistically significant lower odds of self-
reporting hypertension compared to non-Hispanic whites (adjusted odds ratios 
(AOR), 0.62; 95% CI, 0.57-0.66; P < 0.01 males; AOR, 0.62; 95% CI, 0.58-0.66; P < 0.01 
females, respectively). In contrast, non-Hispanic blacks aged 45 to 64 years (AOR, 
1.42; 95% CI, 1.33-1.53; P < 0.01 males; AOR, 2.39; 95% CI, 2.24-2.54; P < 0.01 females, 
respectively) had statistically significant higher odds of self-reporting hypertension 
compared to non-Hispanic whites aged 45 to 64 years. ConClusions: This result 
challenges the commonly held belief that all blacks have a higher prevalence of 
hypertension, and underscores the need for data segmentation to further deter-
mine with more precision the age at which non-Hispanic blacks shift from being 
less likely to self-reporting hypertension to more likely than non-Hispanic whites.
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objeCtives: To compare the number of antihypertensive medications that were 
approved by the US Food and Drug Administration, the UK Medicines and Healthcare 
Products Regulatory Agency, the Australian Therapeutic Goods Administration, 
Health Canada, and the Saudi Food & Drug Authority as of [2014]. Methods: 
Antihypertensive medications information was collected from the websites of the 
agencies. Hypertension prevalence by country was collected from the WHO website. 
Descriptive analysis was conducted in the study. Spearman correlation was used 
to estimate the correlation between the number of approvals and hypertension 
prevalence. SAS version 9.3 was used in the analysis. Results: The prevalence 
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objeCtives: 1) To investigate recent trends in antihypertensive medication pre-
scribing among US adults with hypertension in office-based practices; 2) To deter-
mine if there are differences in the classes of antihypertensive agents prescribed for 
the elderly population as compared with younger patients. Methods: The latest 
available National Ambulatory Medical Care Survey (NAMCS) (2003 – 2010) were ana-
lyzed. All encounters with ICD-9 codes for essential hypertension (eg, 401.0, 401.1, 
or 401.9) and patients aged ≥ 18 years were identified. Multivariate logistic regres-
sion analyses determined the adjusted associations between age (< 60 years, ≥ 60 
years) and the prescription use of antihypertensive classes, as well as prescribing 
year trend. Variance estimates were computed with the Taylor series linearization 
approximation. Results: Approximately 674 million weighted office visits were 
included in the analysis. Overall, the prescription of antihypertensive medication 
increased from 69.2% in 2003 to 2004 to 78.8% in 2009 to 2010 (P trend< 0.01) and 
the upward trend was consistent in both age groups. This was accompanied by an 
improvement in the overall hypertension control (from 39.6% to 49.3%, P trend< 0.01). 
The proportions of visits with β -blocker (from 25.4% to 34.7%, P trend< 0.01) and 
angiotensin receptor blocker (ARB) prescriptions (from 17.0% to 22.1%, P trend= 0.02) 
increased for older patients. Prescribing rates for diuretics, β -blockers, and calcium-
channel blockers (CCBs) were significantly higher among patients aged ≥ 60 years 
compared to their younger counterparts, while rates for ARBs and angiotensin-
converting enzymes (ACEIs) were relatively comparable between the two groups. 
The increase in use of β -blockers in older patients persisted after excluding patients 
with congestive heart failure and ischemic heart disease. ConClusions: In office-
based practices, antihypertensive medication prescribing among US adults with 
hypertension increased significantly in recent years which was accompanied by 
some improvement in hypertension control. The prescribing patterns differed 
among younger and older patients but continuous use of β -blockers without other 
compelling indications raises concerns.
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objeCtives: (1) To compare risks posed by the metabolic syndrome (MetS) diagnosed 
with four different criteria and cardiovascular risk factors in the development of 
diabetes mellitus 2 (T2D), cardiovascular disorders and other chronic disorders. (2) To 
determine if modification should be made to existing MetS definitions and standards 
of diagnosis of high risk patients. Methods: A combination of NHANES 2009-2010 
and 2010-2011 databases formed our study cohort. MetS criteria included harmo-
nized 2009 World Health Organization definition, criteria from National Cholesterol 
Education Program Adult Treatment Panel III (NCEP-ATP III), International Diabetes 
Federation (IDF) and European Group for Study of Insulin Resistance (EGIR). Individual 
cardiovascular risk factors included smoking, alcoholism, albuminurea, elevated 
C-reactive protein levels and heredity of diabetes and cardiovascular disorders. Risk 
prediction was carried out for chronic disorders such as diabetes, cardiovascular dis-
orders, arthritis, asthma, emphysema, bronchitis, cancer and AIDs. Adjusted relative 
risk (RRs) using Poisson regression was calculated for each criteria and individual risk 
factors. Results: MetS failed to predict risk for cardiovascular disorders. However 
albuminurea (RR= 2.25), smoking (RR= 2.16) and heredity (RR= 1.52) posed a risk for 
cardiovascular disorders. All except smoking (0.32) demonstrated high risk for asthma. 
Smoking (RR= 4.15) along with all the MetS criteria (RR with WHO= 2.63; NCEP= 3.16; 
IDF= 5.67) except European criteria (RR= 0.67) predicted risk for emphysema. MetS 
(RR with WHO= 2.24; Europe= 5.43; NCEP= 3.31; IDF= 2.66) and albuminurea (RR= 1.49) 
were good predictors of kidney conditions. Similarly MetS (RR with WHO= 3.67; 
Europe= 6.33; NCEP= 4.24; IDF= 1.89), albuminurea (RR= 2.94), alcoholism (RR= 3.08) and 
heredity (RR= 3.74) were associated with risk for liver conditions. No MetS criteria and 
individual risk factors showed an association with risk for AIDS. ConClusions: 
Overall European MetS criteria emerged as the strongest risk predictor for chronic 
conditions. The RRs of individual risk factors depict significant chronic disease pre-
dicting ability. Recommendations may be made to policy makers to alter or make 
additions to the current MetS definition.
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objeCtives: To investigate the prevalence of hyperkalemia in patients with chronic 
kidney disease (CKD) or heart failure (HF). Methods: De-identified medical records 
(2007-2012) from a US population aged ≥ 5 years with ≥ 2 potassium (K+) readings were 
evaluated. Inclusion criteria: ≥ 1 K+ value between 2.5 and 10 mEq/L during 2008 to 
2012. Exclusion criteria: acute kidney injury (AKI). Hyperkalemia was classified as mild 
(K+ 5.1 to 5.4 mEq/L) or moderate/severe (K+ ≥ 5.5 mEq/L) based on patient’s highest 
measured value. Patient comorbidities were assessed: CKD by stage, end-stage renal 
disease (ESRD), HF, diabetes, and disease combinations. Control patients had no CKD 
stage 2+, ESRD, HF, diabetes or AKI. Chi-square tests assessed whether prevalence of 
hyperkalemia differed significantly between control patients and those with comor-
bidities. Hyperkalemia prevalence was also compared by age group (< 65 years vs 
≥ 65 years). Results: 1,636,337 patients were evaluated; mean age, 56 years; 56% 
